Abstract
Theories of bilingual language production predict that bilinguals with Alzheimer's disease (AD) should exhibit one of two decline patterns. Either parallel decline of both languages (if decline reflects damage to semantic representations that are accessed by both languages), or asymmetrical decline, with greater decline of the nondominant language (if decline reflects reduced ability to resolve competition from the dominant language with disease progression). Only two previous studies examined decline longitudinally with one showing parallel, and the other asymmetrical, decline. We examined decline over 2-7 years (3.9 on average) in Spanish-English bilinguals (N = 23). Logistic regression revealed a parallel decline pattern at one year from baseline, but an asymmetrical decline pattern over the longer decline period, with greater decline of the nondominant language (when calculating predicted probabilities of a correct response). The asymmetrical decline pattern was significantly greater for the nondominant language only when including item-difficulty in the model. Exploratory analyses across dominance groups looking at proportional decline relative to initial naming accuracy further suggested that decline of the nondominant language may be more precipitous if that language was acquired later in life, but the critical interaction needed to support this possibility was not statistically significant in a logistic regression analysis. These results suggest that accessibility of the nondominant language may initially be more resilient in early versus more advanced AD, and that AD affects shared semantic representations before executive control declines to a point where the ability to name pictures in single-language testing block is disrupted. Additional work is needed to determine if asymmetrical decline patterns are magnified by late age of acquisition of the nondominant language, and if more subtle impairments to executive control underlie impairments to language switching that occur in the earliest stages of AD (even preclinically).